GlobeNewsWire · QURE · November 2, 2026

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease

Get the app for more

Explore stock news, insights and company research.